Every 8-K that Medtronic plc (MDT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDT filings page.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 8-K filing submitted to the SEC.
Medtronic plc (MDT) reported strong Q1 fiscal 2027 results for the quarter ended July 31, 2026, with worldwide revenue of $9.756 billion, up 13.7% as reported and organically. The company estimates an extra fiscal week in Q1 benefited organic growth by approximately $570 million. GAAP diluted EPS was $1.14 and non-GAAP diluted EPS was $1.45, rising 40.7% and 15.1%, respectively.
Growth was broad-based: Cardiovascular revenue rose 19.5% to $3.927 billion, Neuroscience rose 10.3% to $2.678 billion, Medical Surgical rose 10.0% to $2.279 billion, and Diabetes grew 16.9% to $843 million. Free cash flow increased to $1.29 billion. Based on this performance, Medtronic raised FY27 organic revenue growth guidance to 7.25%–7.75% and non-GAAP EPS guidance to $5.94–$6.00, including an estimated neutral to 1% accretive foreign currency impact.
Medtronic plc reported strong Q4 and fiscal 2026 results with its fastest annual revenue growth in 10 years. Q4 revenue reached $9.807 billion, up 9.9% as reported and 6.6% organic, with GAAP EPS of $0.96 and non-GAAP EPS of $1.55, both ahead of guidance.
For FY26, revenue was $36.364 billion, up 8.4% reported and 5.8% organic. GAAP EPS was $3.73, up 3.3%, while non-GAAP EPS was $5.53, up 0.7%, as operating margin was flat on a GAAP basis and modestly lower on a non-GAAP basis.
Cardiovascular revenue grew 12.0% for the year, Neuroscience 4.5%, Medical Surgical 4.9%, and Diabetes 12.9% reported. Free cash flow was $5.426 billion, and the quarterly dividend was raised to $0.72 per share, marking the 49th consecutive annual dividend increase.
Looking to FY27, Medtronic guides to 6.75% to 7.25% organic revenue growth and diluted non-GAAP EPS of $5.90 to $6.00, implying 6.7% to 8.5% EPS growth, including the impact of a 53rd week and full-year Diabetes business consolidation.
Medtronic plc reported a leadership change in its Neuroscience Portfolio. Brett Wall will depart his role as Executive Vice President and President, Neuroscience Portfolio, and remain with the company until September 1, 2026 to support an orderly transition. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will become Executive Vice President and President, Neuroscience Portfolio effective June 1, 2026. Mr. Wall will receive severance payments and benefits consistent with Medtronic’s standard executive officer severance practices described in its 2025 proxy statement.
Medtronic plc reported that an unauthorized third party accessed data in certain corporate IT systems. After discovering the issue, the company contained the incident, activated its response protocols, and brought in external cybersecurity experts to investigate and remediate.
Medtronic states it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or its ability to meet patient needs. Based on current findings, it does not expect a material impact on its business or financial results. The company is assessing whether personal information was accessed and will notify and support affected individuals as needed.
Medtronic plc reported that its subsidiary MiniMed Group received earlier-than-expected U.S. FDA clearance for the MiniMed Flex, a next-generation, smartphone-controlled insulin pump. The product’s research and development was partly funded by Blackstone Life Sciences under a deal that entitles Blackstone to mid-to-high single digit royalties or specified minimum payments for two years after U.S. approval and launch.
MiniMed expects to record a one-time charge of $157 million in Medtronic’s fourth quarter of fiscal 2026 for future payments to Blackstone, with an estimated $0.08 per share impact based on Medtronic’s 90% MiniMed ownership. Separately, the recent IPO of 10% of MiniMed is expected to dilute Medtronic shareholders by about $0.04 per share in that quarter.
As a result, Medtronic now guides full-year fiscal 2026 non-GAAP EPS to $5.50–$5.54, reduced from the prior $5.62–$5.66 range. Guidance for fiscal 2027 remains unchanged at high single-digit EPS growth and is based on the earlier, higher EPS baseline before these MiniMed-related items.
Medtronic plc reported strong third quarter fiscal 2026 results, with revenue of $9.017 billion, up 8.7% as reported and 6.0% on an organic basis, slightly ahead of guidance.
GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the guidance mid-point. Cardiovascular revenue rose 13.8% to $3.457 billion and Diabetes revenue grew 14.8% to $796 million, with Cardiac Ablation Solutions up 80% on strength in pulsed field ablation.
The company reiterated its FY26 organic revenue growth outlook of about 5.5% and non-GAAP EPS guidance of $5.62 to $5.66, including a possible $185 million tariff impact. Medtronic also highlighted multiple regulatory milestones, including U.S. FDA clearances for its Hugo robotic-assisted surgery system and Stealth AXiS Surgical System, CE Mark for Sphere-360, and two M&A deals in coronary, renal denervation, and structural heart.
Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026. On November 18, 2025, the company issued a press release with these results, which is included as Exhibit 99.1. The report also confirms Medtronic’s status as an Irish public limited company and lists its ordinary shares and various series of senior notes, with maturities ranging from 2027 to 2053, as being listed on the New York Stock Exchange.
Medtronic plc reported that Gregory L. Smith, Executive Vice President, Enterprise Operations, will retire from the company effective December 2, 2025 and plans to join a private equity‑held organization. The company states he will receive retirement treatment for outstanding equity as previously disclosed.
Under those equity terms, unvested stock options will accelerate, while restricted stock units (RSUs) and performance stock units (PSUs) will continue to vest in line with the applicable award agreements filed with the SEC.
Medtronic plc reported the results of its Annual General Meeting held on October 16, 2025. Shareholders approved amendments to the company’s Memorandum and Articles of Association, including changes to Article 177 to allow the Board to capitalize certain non-distributable reserves to create distributable reserves and updates to the advance notice provisions. They also approved a capital reduction to create distributable reserves under Irish law.
All twelve director nominees were elected and shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 and authorized the Board, through the Audit Committee, to set auditor remuneration. Shareholders renewed the Board’s authority to issue shares and to opt out of pre-emption rights under Irish law, and authorized the company and its subsidiaries to make overseas market purchases of ordinary shares. At the record date, 1,282,616,011 ordinary shares were outstanding; 1,109,198,321 were represented at the meeting, constituting a quorum.
Medtronic plc filed an 8-K disclosing a Sixth Supplemental Indenture dated September 29, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Computershare Trust Company, N.A. as successor trustee and U.S. Bank Europe DAC, UK Branch as paying agent. The filing includes the forms of the 2030 Notes and the 2045 Notes, and attaches legal opinions from U.S., Irish and Luxembourg counsel plus consents from each counsel and an internal opinion by an Assistant Secretary. The submission also references an embedded Cover Page Interactive Data File and is signed by Thierry Pi e9ton, Executive Vice President and Chief Financial Officer.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc reported that it issued a press release announcing its first quarter fiscal year 2026 financial results, which is provided as an exhibit to this report. The company also expanded its Board of Directors from 11 to 13 members and appointed John Groetelaars and William Jellison as new directors, effective August 19, 2025.
Mr. Jellison will serve on newly created Growth and Operations board committees, while Mr. Groetelaars will serve on the Growth committee. Both will be eligible for the standard non‑employee director cash retainer and equity grant described in Medtronic’s recent proxy materials. The company states there are no reportable related‑party transactions or selection arrangements involving either new director. The earnings and director appointment press releases are included as Exhibits 99.1 and 99.2.
Medtronic announced a significant board expansion and appointment in an 8-K filing dated June 28, 2025. The Board of Directors increased from 10 to 11 members with the appointment of Dr. Joon Lee, effective June 18, 2025.
Key details of the appointment:
- Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee
- Will receive standard non-employee director compensation including annual cash retainer and equity grants as outlined in the August 2024 proxy statement
- No special arrangements or understandings influenced the appointment
- No reportable transactions under Item 404(a) of Regulation S-K between Dr. Lee or immediate family and the company
The appointment was formally announced via press release on June 23, 2025. The filing was executed by Ivan K. Fong, Executive Vice President, General Counsel and Secretary.